ProCE Banner Activity

Phase II Trial of Emricasan in NASH Cirrhosis and Severe Portal Hypertension

Slideset Download
Conference Coverage
Although this trial did not meet the primary endpoint of decreasing mean hepatic venous pressure gradient in patients with NASH cirrhosis and severe portal hypertension, positive signals were seen that support additional exploration of emricasan in patients with severe portal hypertension.

Released: April 17, 2019

Expiration: April 15, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

AbbVie

Gilead